Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Nonrandomized, Open-label, Multicenter, Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Subjects with Advanced Solid Tumors and Hematologic Malignancies

NCT05690581 is registered in ClinicalTrials.gov with Beijing InnoCare Pharma Tech Co., Ltd. as lead sponsor.

NCT NCT05690581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05690581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Nonrandomized, Open-label, Multicenter, Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Subjects with Advanced Solid Tumors and Hematologic Malignancies
Lead sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
February 23, 2023
Completion date
February 28, 2026
Enrollment
146 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors and hematologic malignancies